Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

180 Life Sciences Corp (NQ: ATNF )

1.810 -0.030 (-1.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 40,057
Open 1.890
Bid (Size) 1.810 (1)
Ask (Size) 1.820 (6)
Prev. Close 1.840
Today's Range 1.800 - 1.890
52wk Range 1.180 - 55.98
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at Summer Research Conference
Via Investor Brand Network

Performance

YTD
-65.85%
-65.85%
1 Month
-36.93%
-36.93%
3 Month
+9.04%
+9.04%
6 Month
-87.06%
-87.06%
1 Year
-96.61%
-96.61%

More News

Read More
180 Life Sciences Announces Presentation at the Gordon Conference
From 180 Life Sciences Corp.
Via Globe NewsWire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Update on Change of Status for Anti-TNF Frozen Shoulder Trial, Receives Patent Notification
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and Application
From 180 Life Sciences Corp.
Via Globe NewsWire
180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial
From 180 Life Sciences Corp.
Via Globe NewsWire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Medical Advisory Board Chair Coauthors Review of Early Stage Dupuytren’s Disease Treatment
Via Investor Brand Network
180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease
From 180 Life Sciences Corp.
Via Globe NewsWire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Engages Kinexum for Assistance in MAA Submission
Via Investor Brand Network
180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom
From 180 Life Sciences Corp.
Via Globe NewsWire
Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)
From Newman Ferrara LLP
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Is Notified by NASDAQ Exchange of Full Compliance
Via Investor Brand Network
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
From 180 Life Sciences Corp.
Via Globe NewsWire
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Review on Molecular Basis of Dupuytren’s Disease
Via Investor Brand Network
180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease
From 180 Life Sciences Corp.
Via Globe NewsWire
EXCLUSIVE: Top 10 Searched Tickers On Benzinga Pro In December 2022: Where Do Tesla, Apple, AMC Rank?
Via Benzinga
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Wall Street Starts 2023 On Positive Note
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.